May 22, 2018 9:02 AM ET


Company Overview of Navitor Pharmaceuticals, Inc.

Company Overview

Navitor Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines by targeting cellular nutrient signaling pathways. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company’s therapeutics are designed to modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a range of diseases, including metabolic, neurodegenerative, autoimmune, and musculoskeletal diseases, as well as various rare disorders. The company offers solutions in the areas of mTORC1 and nutrient signaling; s...

700 Main Street

Cambridge, MA 02139

United States

Founded in 2009



Key Executives for Navitor Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 61
Founder and Chairman of the Board
Age: 54
Founder and Executive Director
Scientific Founder and Member of Scientific Advisory Board
Vice President of Business, Operations and Finance
Compensation as of Fiscal Year 2017.

Navitor Pharmaceuticals, Inc. Key Developments

Navitor Pharmaceuticals, Inc. Presents at 38th Annual Cowen and Company Healthcare Conference, Mar-14-2018 08:30 AM

Navitor Pharmaceuticals, Inc. Presents at 38th Annual Cowen and Company Healthcare Conference, Mar-14-2018 08:30 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: George P. Vlasuk, Chief Executive Officer, President and Director.

Navitor Pharmaceuticals to Develop NV-5138, Specific Activator of mTORC1 for Treatment-Resistant Depression

Navitor Pharmaceuticals, Inc. announced that its direct mTORC1 activator small molecule NV-5138, has been designated as the company’s lead drug candidate to be developed for treatment-resistant depression (TRD). With the announcement of NV-5138 as Navitor’s first drug program, the company is also revealing its drug development strategy of targeting nutrient sensor proteins, which enabled the identification of NV-5138, a small molecule targeting Sestrin2 to selectively modulate mTORC1 signaling in neurons to specifically intervene in the disease process underlying TRD. Navitor gained insight into the new biology of nutrient sensors based on cutting-edge discoveries by the company’s scientific founder, David M. Sabatini, MD, PhD, Professor of Biology at MIT, Member of the Whitehead Institute for Biomedical Research, and Investigator at Howard Hughes Medical Institute. Concurrently, Navitor leveraged preclinical observations that have shown mTORC1 activation as critical for the efficacy of rapid-acting modulators of the NMDA (N-methyl-D-aspartic acid)-mediated signaling pathway like ketamine, which is an active area of innovative drug development for depression.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
March 2, 2018

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Navitor Pharmaceuticals, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at